组织因子通路抑制剂的缺乏在小鼠中促进动脉样硬化和血栓形成
R J Westrick1, P F Bodary, Z Xu
1Division of Cardiology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
Circulation
|June 27, 2001
概括
组织因子通路抑制剂 (TFPI) 缺乏会加剧动脉样硬化,并促进小鼠的血栓形成. 降低TFPI水平会增加斑块负担并加速血块形成,突出显示TFPI的保护作用.
科学领域:
- 心血管生物学 心血管生物学
- 血液静止和血栓形成
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 组织因子 (TF) 在动脉样硬化斑块破裂后启动血液凝结.
- 组织因子通路抑制剂 (TFPI) 对抗TF活性,可能减轻血栓形成.
- 在动脉样硬化和血栓性并发症中TFPI的作用尚未完全阐明.
研究的目的:
- 调查异构性TFPI缺乏对动脉样硬化进展的影响.
- 在动脉样硬化小鼠模型中评估TFPI缺乏对血栓形成的影响.
主要方法:
- 通过交叉繁殖TFPI异合体和apoE同合体缺乏TFPI的小鼠,产生TFPI(+/-) /apoE(-/-) 的小鼠.
- 全面分析整个血管树的动脉样硬化负担.
- 评估光化学性大脑动脉损伤后的斑块TF活性和遮性血栓形成的时间.
主要成果:
- 缺少TFPI显著增加了大脑动脉样硬化负担在动脉和常见的腹动脉.
- 在TFPI缺乏的小鼠的动脉样硬化斑块内观察到升高的TF活性.
- 缺少TFPI显著降低了在心动脉损伤后发生闭塞性血栓形成的时间.
结论:
- TFPI提供了防止动脉样硬化发展的保护.
- 在动脉样硬化背景下,TFPI是血栓形成的关键调节者.
相关概念视频
Transcription Factors
82.3K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.3K
The Eukaryotic Promoter Region
18.7K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.7K
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Atherosclerosis I: Introduction
970
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
970
Atherosclerosis III: Management
337
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
337
Venous Thrombosis I: Introduction
410
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
410


